BLUE BELL, Pa., Sept. 30, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of synthetic vaccines against cancers and infectious diseases, announced today that scientists, advisors and collaborators of the company will make presentations at multiple scientific conferences:
5th Vaccine Global Congress October 2-5 Seattle, WA Marriott Waterfront Hotel
Presentations David Weiner, Ph.D. University of Pennsylvania "Robust DNA vaccine +/- protein boost delivered by EP expands B and T cell responses in humans and animals and can induce neutralizing immune responses in vivo" October 2, 2011
Dr. Matt Morrow, Product Development Scientist, Inovio "Induction of HPV specific CTLs in human volunteers after DNA immunization" October 3, 2011
Cancer Immunotherapy 2011 October 3-5 New York, NY The Millennium Broadway and Conference Center
Presentation Mark Bagarazzi, MD, Chief Medical Officer, Inovio "Delivering potent and durable immune responses with HPV 16 and 18 SynCon® DNA vaccines via electroporation" October 6, 2011
World Vaccine Congress 2011 October 10-13 Lyon, France Palais des Congres de lyon
Presentation Mark Bagarazzi, MD, Chief Medical Officer, Inovio "HIV - after years of failure, what does the future hold for the Holy Grail of vaccines?" October 11, 2011
SVS-2011: Skin Vaccination Summit October 12-14 Washington, DC Kellogg Conference Hotel
Presentations Kate Broderick, Director of Research & Development, Inovio "DNA delivery to skin is enhanced by next generation electroporation devices that target dermal tissue" October 13, 2011
Niranjan Sardesai, Sr. VP of Research & Development, Inovio "Prophylactic vaccines for emerging infectious diseases" October 14, 2011
5th Vaccines Renaissance Conference October 17-19 Providence, RI Hotel Providence
Presentation Niranjan Sardesai, Sr. VP of Research & Development, Inovio "Induction of HPV specific CTLs in humans after DNA immunotherapy" October 18, 2011
About Inovio Pharmaceuticals, Inc.
Inovio is developing its revolutionary synthetic consensus immunogen technologies to extend the profound medical benefits of the 20th century's immune-system-stimulating vaccines by preventing and treating today's cancers and challenging infectious diseases. Its SynCon® vaccines are designed to provide universal cross-strain protection against known as well as newly emergent unmatched strains of pathogens such as influenza. These synthetic vaccines, in combination with Inovio's proprietary CELLECTRA® delivery method, have been shown in humans to be safe and generate best-in-class immune responses. Inovio's clinical programs include Phase II studies for cervical dysplasia/cancer, leukemia and hepatitis C virus and Phase I studies for influenza and HIV. Partners and collaborators include the University of Pennsylvania, Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.
This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, our ability to successfully integrate Inovio and VGX Pharmaceuticals, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2010, our Form 10-Q for the three months ended June 30, 2011, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.
SOURCE Inovio Pharmaceuticals, Inc.